Retinal detachment and fluoroquinolones [1]

JAMA

Volumn 308, Issue 3, 2012, Pages 233-

  Nowroozzadeh, Mohammad H ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACUTE SINUSITIS; ADVERSE OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DRUG INDICATION; HIGH RISK POPULATION; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETINA DETACHMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; FEMALE; MALE; NOTE;

FEMALE; FLUOROQUINOLONES; HUMANS; MALE; RETINAL DETACHMENT;

EID: 84863945141     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.6630     Document Type: Letter

References (4)

1. Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307(13):1414- 1419.
2. Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med. 2002;113(suppl 1A):45S-54S.
3. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis. 2007;44(6):769-774. (Pubitemid 46365298)
4. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63(24):2769-2802. (Pubitemid 38049994)